{
    "200_day_moving_avg": {
        "title": "200-Day Moving Average",
        "value": "11.93"
    },
    "50_day_moving_avg": {
        "title": "50-Day Moving Average",
        "value": "16.54"
    },
    "52_week_change": {
        "title": "52-Week Change",
        "value": "380.40%"
    },
    "52_week_high": {
        "title": "52 Week High",
        "value": "28.10"
    },
    "52_week_low": {
        "title": "52 Week Low",
        "value": "4.46"
    },
    "company_name": {
        "title": "Company Name",
        "value": "Celcuity Inc. (CELC)"
    },
    "float": {
        "title": "Float",
        "value": "6.75M"
    },
    "fullTimeEmployees": {
        "title": "Profile",
        "value": 30
    },
    "held_by_insiders": {
        "title": "% Held by Insiders",
        "value": "42.81%"
    },
    "held_by_institutions": {
        "title": "% Held by Institutions",
        "value": "15.79%"
    },
    "industry": {
        "title": "Industry",
        "value": "Diagnostics & Research"
    },
    "profile": {
        "title": "Profile",
        "value": "Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota."
    },
    "sector": {
        "title": "Sector",
        "value": "Healthcare"
    },
    "shares_outstanding": {
        "title": "Shares Outstanding",
        "value": "12.29M"
    },
    "shares_short": {
        "title": "Shares Short (Mar 31, 2021)",
        "value": "13.47k"
    },
    "short_percent_of_float": {
        "title": "Short % of Float (Mar 31, 2021)",
        "value": "0.17%"
    },
    "short_percent_of_shares_outstanding": {
        "title": "Short % of Shares Outstanding (Mar 31, 2021)",
        "value": "0.11%"
    },
    "short_ratio": {
        "title": "Short Ratio (Mar 31, 2021)",
        "value": "0.55"
    }
}